Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

被引:148
作者
Rodríguez, LAG
Varas-Lorenzo, C
Maguire, A
González-Pérez, A
机构
[1] Ctr Espanol Invest Farmacoepidemiol, Madrid 28004, Spain
[2] Pfizer, Global Epidemiol, Barcelona, Spain
关键词
myocardial infarction; aspirin; epidemiology;
D O I
10.1161/01.CIR.0000132491.96623.04
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Nonsteroidal antiinflammatory drugs ( NSAIDs) are reversible inhibitors of cyclooxygenase ( COX)- 1 and COX-2. Whether transient and incomplete COX-1 inhibition with NSAIDs other than aspirin will translate into clinical cardioprotection is unclear. Some reports suggest that concurrent aspirin and ibuprofen might be associated with lower cardioprotection than aspirin alone because of a pharmacodynamic interaction. Methods and Results - We conducted a cohort study with a nested case-control analysis. Overall, 4975 cases of acute myocardial infarction (MI) and death from coronary heart disease (CHD) were identified ( January 1997 to December 2000) in the UK. A total of 20 000 controls were randomly sampled, and frequency was matched to cases by age, sex, and calendar year. The incidence rate was 5.0 per 1000 person- years. The multivariate-adjusted OR for current NSAID use compared with nonuse was 1.07 ( 95% CI, 0.95 to 1.20). Treatment duration or daily dose did not change the results. The effect was similar among patients free of CHD history ( 1.04; 95% CI, 0.90 to 1.20) and patients with previous history (1.12; 95% CI, 0.91 to 1.38). Estimates for individual NSAIDs were all comparable, with no major effect on the risk of acute MI. Naproxen was associated with an OR of 0.89 ( 95% CI, 0.64 to 1.24). The OR of aspirin and concurrent NSAIDs use was 1.10 ( 95% CI, 0.89 to 1.37) compared with aspirin alone. We observed the same result when analyzing ibuprofen and aspirin taken concomitantly. Conclusions - This study could not demonstrate any detectable risk reduction of NSAIDs on the occurrence of MI. Our results do not support the existence of a clinically meaningful interaction between aspirin and NSAIDs, including ibuprofen.
引用
收藏
页码:3000 / 3006
页数:7
相关论文
共 26 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[3]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[4]   Survival in rheumatoid arthritis - A population-based analysis of trends over 40 years [J].
Gabriel, SE ;
Crowson, CS ;
Kremers, HM ;
Doran, MF ;
Turesson, C ;
O'Fallon, WM ;
Matteson, EL .
ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :54-58
[5]   INTERNATIONAL DIAGNOSTIC-CRITERIA FOR ACUTE MYOCARDIAL-INFARCTION AND ACUTE STROKE [J].
GILLUM, RF ;
FORTMANN, SP ;
PRINEAS, RJ ;
KOTTKE, TE .
AMERICAN HEART JOURNAL, 1984, 108 (01) :150-158
[6]   VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM [J].
JICK, H ;
JICK, SS ;
DERBY, LE .
BRITISH MEDICAL JOURNAL, 1991, 302 (6779) :766-768
[7]   Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs [J].
Kurth, T ;
Glynn, RJ ;
Walker, AM ;
Chan, KA ;
Buring, JE ;
Hennekens, CH ;
Gaziano, JM .
CIRCULATION, 2003, 108 (10) :1191-1195
[8]   Effect of ibuprofen on cardioprotective effect of aspirin [J].
MacDonald, TM ;
Wei, L .
LANCET, 2003, 361 (9357) :573-574
[9]   Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly [J].
Mamdani, M ;
Rochon, P ;
Juurlink, DN ;
Anderson, GM ;
Kopp, A ;
Naglie, G ;
Austin, PC ;
Laupacis, A .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (04) :481-486
[10]   Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 [J].
McAdam, BF ;
Catella-Lawson, F ;
Mardini, IA ;
Kapoor, S ;
Lawson, JA ;
FitzGerald, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :272-277